Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1880-4233
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer ; volume:26 ; number:5 ; day:24 ; month:5 ; year:2019 ; pages:637-650 ; date:9.2019
Breast cancer ; 26, Heft 5 (24.5.2019), 637-650, 9.2019
- Creator
-
Masuda, Norikazu
Mukai, Hirofumi
Inoue, Kenichi
Rai, Yoshiaki
Ohno, Shinji
Mori, Yuko
Hashigaki, Satoshi
Muramatsu, Yasuaki
Umeyama, Yoshiko
Iwata, Hiroji
Toi, Masakuzu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12282-019-00970-7
- URN
-
urn:nbn:de:101:1-2020010106035087332606
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Masuda, Norikazu
- Mukai, Hirofumi
- Inoue, Kenichi
- Rai, Yoshiaki
- Ohno, Shinji
- Mori, Yuko
- Hashigaki, Satoshi
- Muramatsu, Yasuaki
- Umeyama, Yoshiko
- Iwata, Hiroji
- Toi, Masakuzu
- SpringerLink (Online service)
Other Objects (12)
Neutropenia due to palbociclib: A word of caution?
Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
Febrile neutropenia : with 32 tables
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Paediatric autoimmune diseases with ELANE mutations associated with neutropenia
Regression of choroidal metastasis from breast carcinoma with palbociclib
Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
A single institution experience with palbociclib toxicity requiring dose modifications
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
Neutropenia due to palbociclib: A word of caution?
Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
Febrile neutropenia : with 32 tables
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Paediatric autoimmune diseases with ELANE mutations associated with neutropenia
Regression of choroidal metastasis from breast carcinoma with palbociclib
Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
A single institution experience with palbociclib toxicity requiring dose modifications
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
Neutropenia due to palbociclib: A word of caution?
Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
Febrile neutropenia : with 32 tables
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Paediatric autoimmune diseases with ELANE mutations associated with neutropenia
Regression of choroidal metastasis from breast carcinoma with palbociclib
Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
A single institution experience with palbociclib toxicity requiring dose modifications